Curated News
By: NewsRamp Editorial Staff
May 12, 2025
Quantum BioPharma Advances Lead MS Treatment toward IND Application
TLDR
- Quantum BioPharma (NASDAQ: QNTM) completed dosing for Lucid-MS, advancing towards Phase 2 trial, positioning as a first-in-class therapy for MS.
- Lucid-21-302 completed 90-day oral toxicity studies for multiple sclerosis, supporting IND application to the U.S. FDA by year-end.
- Lucid-MS aims to prevent and reverse myelin degradation, offering hope for improved treatment of multiple sclerosis and neurodegenerative disorders.
- Quantum BioPharma's Lucid-21-302, a novel treatment for MS, marks a significant advancement in the pursuit of innovative therapies for challenging disorders.
Impact - Why it Matters
This news matters as Quantum BioPharma's progress in developing Lucid-21-302 could lead to a new therapy for multiple sclerosis patients. The completion of key studies signifies a significant step in the drug's clinical development, potentially offering hope to those affected by the disease.
Summary
Quantum BioPharma (NASDAQ: QNTM) completed dosing in 90-day oral toxicity and toxicokinetic studies for Lucid-21-302, a potential treatment for multiple sclerosis. The results will support an IND application to the U.S. FDA, advancing the drug toward a Phase 2 clinical trial as a first-in-class MS therapy.
The company, focused on innovative neurodegenerative treatments, also holds a stake in Celly Nutrition Corp. and maintains a strategic investment portfolio. Quantum BioPharma aims to develop products for pharmaceutical and medical applications.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Quantum BioPharma Advances Lead MS Treatment toward IND Application
